Based on data from two clinical trials halted about two months ago, the US Food and Drug Administration on Thursday issued a statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma.
US pharma giant Merck & Co’s (NYSE: MRK) already blockbuster cancer drug Keytruda is not approved for treatment of multiple myeloma. Sales of the drug nearly tripled to $881 million in the second quarter of 2017, beating consensus estimates of $777 million.
Merck stopped enrolling multiple myeloma patients in the trials in June and notified the FDA. Shortly thereafter, the agency placed a full hold on these trials and patients are no longer receiving treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze